Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7260312 | 0.98 | NEK2 (0.31) | NEK2 | |
| SCHEMBL17277743 | 0.81 | NEK2 (0.31) | NEK2 | |
| SCHEMBL15416446 | 0.79 | NEK2 (0.35) | NEK2OPRM1ALDH1A1 | |
| SCHEMBL2435959 | 0.77 | POLB (0.32) | — | |
| SCHEMBL14689547 | 0.74 | — | — | |
| SCHEMBL6113562 | 0.72 | — | — | |
| SCHEMBL14829982 | 0.71 | NEK2 (0.42) | NEK2OPRM1 | |
| SCHEMBL22829243 | 0.71 | — | — | |
| SCHEMBL16835486 | 0.67 | DDB1 (0.31) | — | |
| SCHEMBL8608569 | 0.67 | ATM (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003524-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC INFECTIONS | Bayer Animal Health GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3818051-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | Bayer Aktiengesellschaft (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3818049-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | Bayer Aktiengesellschaft (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3818050-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | Bayer Aktiengesellschaft (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3774748-A1 | OXADIAZOLINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021018839-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC INFECTIONS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-02-04 | — | — | WO | disclosed |
| EP-3752492-A1 | FUNGICIDAL OXADIAZOLES | Bayer Aktiengesellschaft (DE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020079173-A1 | PYRIDYLPHENYLAMINOQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020007902-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020007904-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2010063670-A1 | SPIROHETEROCYCLIC N-OXYAMIDES AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-1804794-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | Merck & Co., Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044497-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003099801-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | NEK2 1046/4885OPRM1 4512/4885ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.